je.st
news
Tag: merck
Merck & Co., Inc. (MRK) Shares Sold by Modera Wealth Management
2015-12-20 05:42:34| Biotech - Topix.net
Modera Wealth Management decreased its stake in Merck & Co., Inc. by 0.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,640 shares of the company's stock after selling 42 shares during the period.
Tags: management
sold
shares
wealth
Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir
2015-12-18 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has responded to the companys marketing authorization application (MAA) for elbasvir/grazoprevir (50mg/100mg), which is under review for the treatment of adult patients with chronic hepatitis C (HCV) infection. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: application
marketing
update
agency
Merck wins approval for long-delayed surgery revival drug
2015-12-16 00:13:16| Biotech - Topix.net
Federal health authorities have approved a new drug that helps patients recover from the numbing effects of certain surgical drugs. The approval of Bridion marks a victory for Merck & Co.
Tags: drug
approval
surgery
wins
FDA panel rejects Merck claim Zetia/Vytorin cut heart risk
2015-12-15 10:29:34| Biotech - Topix.net
Dec 14 Merck & Co should not be allowed to claim that its cholesterol-lowering drugs Zetia and Vytorin reduce the risk of heart attacks and strokes in patients with coronary heart disease, an advisory committee to the U.S. Food and Drug Administration concluded on Monday.
Merck Statement on FDA Advisory Committee Meeting on IMPROVE-IT Study with VYTORIN (ezetimibe and simvastatin)
2015-12-15 00:23:15| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, issued today the following statement after the conclusion of a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) to discuss the results of IMPROVE-IT, an investigational study comparing treatment with VYTORIN (ezetimibe and simvastatin) to treatment with simvastatin alone in more than 18,000 patients presenting with acute coronary syndromes. Language: English read more
Tags: statement
study
meeting
committee
Sites : [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] next »